Luxturna market seen growing on gene therapy demand and rare eye disease focus

The Business Research Company says the Luxturna market is set to expand through 2035 as gene therapy adoption rises, rare retinal disorder diagnosis increases and healthcare spending climbs. North America led the market in 2025, while Asia-Pacific is expected to grow fastest.

Why it matters: - Luxturna sits in a niche but growing market tied to inherited retinal disease treatment, where few options exist and long-term outcomes matter. - The market outlook points to broader demand for gene therapies, early genetic screening and specialized retinal delivery technologies. - Growth in this segment can signal how quickly advanced one-time therapies move from rare-use cases into wider ophthalmology practice.

What happened: - The Business Research Company released its Luxturna Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 on November 4, 2026. - The report says the Luxturna market is gaining traction as gene therapy advances and attention to rare genetic eye disorders increases. - The report includes a free sample and a full version available through the company’s sample request page and the full market report. - Luxturna is a gene therapy for inherited retinal diseases caused by mutations in the RPE65 gene. - The treatment delivers a functional copy of the RPE65 gene into retinal cells to help those cells produce the protein needed for vision restoration.

The details: - Historical growth in the Luxturna market has been driven by limited treatment options for inherited retinal diseases, progress in viral vector technology, early gene therapy approvals, more funding for rare disease research and broader use of genetic diagnostic tools. - The market is expected to expand further because gene therapy pipelines are widening, investment in rare disease treatments is increasing, early genetic screening is becoming more common, long-term outcome tracking is getting more attention and retinal delivery technology is improving. - The report flags rising acceptance of gene therapy, stronger focus on rare genetic eye conditions, more investment in one-time curative therapies, growth in precision ophthalmology and more integrated genetic screening and diagnostic processes as key trends during the forecast period. - An increasing prevalence of genetic eye disorders is a major growth driver for the market. - These disorders are inherited conditions caused by gene mutations that affect eye structure or function and can lead to visual impairment or blindness. - The report links the rise in these disorders to higher rates of genetic mutations, aging populations, better diagnostic technology and greater awareness of hereditary conditions. - The report cites United Nations Development Programme data released in December 2023 showing 19,551 people were diagnosed with vision impairments in 2022, with more than 19,000 new cases reported in the first seven months of 2023. - Rising healthcare expenditure is also supporting the market because advanced therapies such as Luxturna are expensive and require specialized administration. - The Office for National Statistics said in May 2024 that UK healthcare expenditure grew 5.6% in nominal terms from 2022 to 2023, compared with 0.9% growth the year before. - North America was the largest regional contributor to the Luxturna market in 2025. - Asia-Pacific is forecast to be the fastest-growing region over the coming years. - The report also covers Western Europe, Eastern Europe, South America, the Middle East and Africa.

Between the lines: - The report’s framing suggests the Luxturna market is being pulled by two forces at once: better diagnosis of rare eye diseases and broader payer or health-system willingness to fund high-cost advanced therapies. - The emphasis on TAM analysis, company scoring matrices, market attractiveness scoring and hotspot graphics shows the report is aimed at investors and strategy teams, not just clinicians. - The geographic split suggests mature markets remain dominant, but growth is shifting toward regions where diagnosis and access to specialty care are expanding.

What’s next: - The report expects continued market expansion through 2035 as gene therapy pipelines mature and retinal delivery approaches improve. - Early screening and integrated diagnostics are likely to play a bigger role in identifying patients earlier in the disease pathway. - Asia-Pacific’s forecast growth suggests more opportunity outside the current North American base.

The bottom line: - Luxturna’s market outlook depends on whether gene therapy adoption, diagnosis rates and reimbursement keep moving in the same direction.